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CHAPTER 1:  LITERATURE REVIEW 1 
Introduction 2 
The global under five mortality rate was estimated to be 43 per 1000 live births in 2015.  3 
The highest rate was noted in Sub Saharan Africa, with infectious diseases implicated as 4 
the leading cause of mortality in children under 5 years of age [1].  Pneumonia was the 5 
second commonest cause of death in children under 5 years of age [1].  Streptococcus 6 
pneumoniae accounted for approximately 11% of childhood deaths in the under five-7 
year age group, worldwide [2].  This encapsulated Gram-positive diplococcus is the 8 
commonest bacterial cause of pneumonia, otitis media, septicemia and meningitis in this 9 
age group [3]. 10 
 Invasive pneumococcal disease (IPD) is defined as “morbidity associated with the 11 
isolation of pneumococci from a normally sterile body site, such as the blood stream, or 12 
those secondary to blood stream spread, e.g. meningitis or septic arthritis” [4].  13 
Incidence rates for IPD are highest in young children (<2 years of age) and the elderly > 14 
65 years, in patients with chronic illnesses such as cardiac failure and chronic 15 
obstructive pulmonary disease, as well as HIV infection and splenectomy [5].   16 
In South Africa, HIV infection has been reported to be a significant risk factor for IPD 17 
in children and adults [6, 7].   18 
Invasive pneumococcal disease in the neonate  19 
The first known case of IPD in a neonate was reported in 1889 in Paris [8].  Since then 20 
several case series and case reports have described neonatal IPD in different parts of the 21 
world [8, 9].  Billings et al reported an estimated global incidence of 36 per 100 000 22 
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live births, at a time when most countries had not introduced the pneumococcal vaccine 23 
into their childhood immunization programs [10].  In their analyses, they observed that 24 
there was a paucity of data on neonatal IPD in low- to middle-income countries 25 
(LMICs) [10].  The incidence of neonatal IPD in South Africa has not previously been 26 
documented. 27 
Clinical features and outcome 28 
Neonatal sepsis is defined as “early-onset” if it occurs at <7 days of age and “late-onset” 29 
if it occurs at ≥ 7 < 28 days of age [11].  Early-onset disease (EOD) in neonates may be 30 
acquired in utero by hematogenous spread or intrapartum, either by ascending infection 31 
or during passage through the birth canal in the presence of vaginal colonization [12, 32 
13].  Late-onset disease (LOD) is acquired postnatally via horizontal spread from the 33 
mother, family members or other caregivers [12, 13]. 34 
In one of the largest case series of neonatal IPD, Gomez et al reported a preponderance 35 
of early-onset disease [8].  This was similar to the findings by Geelen et al in the 36 
Netherlands [14], and Soto-Noguerón A et al in Mexico [15].  In contrast, Hoffman et 37 
al reported on a series of 29 neonates with IPD wherein they found that most cases 38 
presented in the third week of life [9] (Table 1).  These differences may be due to 39 
differences in at-risk populations, socio-economic conditions and access to maternal and 40 
child healthcare [15].  41 
The clinical presentation of IPD in neonates included pneumonia, meningitis, 42 
bacteremia, otitis media and osteomyelitis [8, 9, 16].  Sepsis was reported to be the 43 
predominant clinical presentation in the early-onset group and meningitis in the late-44 
onset group [9].  Neonatal IPD was associated with a high mortality rate, up to 50% in 45 
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one case series [14, 16] (Table 1), with the reported case fatality ratio being highest in 46 
the early-onset group [8]. 47 
 The risk for IPD among children < 1years of age has been found to be greater in HIV-48 
infected than HIV-uninfected children in South Africa [6].  The risk for IPD was also 49 
found to be higher among infants <6 months of age who were HIV-exposed but not 50 
infected, compared to those who were HIV-unexposed and uninfected, in South Africa 51 
[17].  This increased risk may also be present among neonates, but has not been 52 
reported to date, in South Africa or in other parts of the world. 53 
Serotype distribution  54 
Based on the capsular polysaccharide antigen, there are >90 S. pneumoniae serotypes 55 
[18].  The serotypes differ in terms of their ability to colonize the nasopharynx, cause 56 
invasive disease, association with clinical syndromes, antimicrobial resistance patterns, 57 
preponderance in different age groups as well as ability to cause outbreaks [19].  58 
“Pediatric” serotypes have been described as those serotypes most frequently isolated 59 
from children <5 years old and most frequently associated with antimicrobial resistance 60 
[19].  These include serotypes:  4, 6B, 9V, 14, 18C, 19F and 23F (PCV7 serotypes) as 61 
well as serotypes 6A and 19A [19].   62 
The most frequently isolated serotypes prior to the introduction of the pneumococcal 63 
conjugate vaccines into national immunization schedules were the seven serotypes 64 
included in the seven valent pneumococcal conjugate vaccine (PCV7).  These seven 65 
serotypes, 4, 6B, 9V, 14, 18C, 19F, and 23F, accounted for 60 – 75% of IPD in children 66 
in different parts of the world [6, 20].  In 2010 vaccines providing coverage against 67 
additional serotypes, the 10-valent (PCV10) and 13-valent (PCV13) vaccines, were 68 
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introduced [21].  The PCV7 was introduced as part of the routine pediatric 69 
immunization schedule in South Africa in 2009.  However, in 2011 the PCV7 was 70 
replaced by the PCV13, which added serotypes 1, 3, 5, 6A, 7F, 19A to the serotypes 71 
covered. 72 
In England, prior to PCV introduction, the serotypes implicated in neonatal IPD were 73 
reported to be those more frequently isolated in older children and young adults [22].  In 74 
infants <90 days of age PCV 7 and PCV 13 serotypes accounted for 44% and 63% of 75 
serotyped isolates in the same study [22].  Similar coverage was noted in Mexico in 76 
children <=60 days of age, also in the prevaccine era [15].  Hoffman et al reported 75% 77 
of IPD was due to PCV 7 serotypes, in the USA [9].  The most frequent serotypes in 78 
neonatal IPD were 1, 3, 5, 12, 7F, 19F [ 9, 15, 20 ] (Table 1).  These are all vaccine 79 
serotypes included in the PCV13.  However, serotypes 3, 5 and 7F have been reported 80 
as uncommon causes of IPD in South African children < 5 years of age [6]. 81 
Neonates may be protected from IPD by the indirect effects of PCV, or by maternal 82 
immunization.  Herd protection with use of PCV occurs through vaccinated individuals 83 
who are less likely to carry vaccine-type pneumococci, thus reducing transmission and 84 
conferring protection to those who are unimmunized [23].  The decrease in neonatal 85 
IPD in England and Wales post-PCV introduction suggests a role for herd protection 86 
[22].  Maternal immunization strategies have been explored by investigators in Brazil 87 
[24, 25].  However, there is no current recommendation for routine immunization of 88 
pregnant mothers against pneumococcus, as there is insufficient evidence that such 89 
vaccination confers protection to the neonate [26, 27].  90 
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Antimicrobial susceptibility  91 
The first clinical isolate of penicillin non-susceptible S. pneumoniae was reported in 92 
1967 in Papua, New Guinea [28].  Since then numerous reports have documented the 93 
clonal spread of multidrug-resistant S. pneumoniae, in South Africa, as well as globally 94 
[29, 30].  On a global level, the serotypes associated with penicillin resistance were 95 
19A, 19F, 35B, 6A, 6B, 23A, 9V, 15A, and 14 [31].  Multidrug-resistance (MDR) is 96 
defined as resistance to antimicrobials in three or more classes [32].  In 2008, the 97 
incidence of MDR IPD was highest in the <1-year age group [6].  In South Africa, prior 98 
to the introduction of the conjugate vaccines, the strongest independent risk factor for 99 
multidrug resistant IPD was IPD caused by PCV13 serotypes [33]. 100 
In contrast, neonatal IPD has been associated with penicillin-susceptible isolates (Table 101 
1).  This has been attributed to the fact that the commonest serotypes implicated in 102 
neonatal IPD are infrequently associated with antimicrobial resistance [8, 9, 22].  103 
International guidelines for empiric therapy of suspected neonatal sepsis include the use 104 
of ampicillin and gentamicin, or a third generation cephalosporin [34].  Such regimens 105 
would therefore provide adequate coverage for neonates with IPD.  106 
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Summary 107 
Neonatal IPD has been well-described in high-income countries, but there is a paucity 108 
of data in LMICs.  This is the first study in South Africa that aims to provide baseline 109 
data on the pre-vaccine incidence, clinical features, serotype distribution and 110 
antimicrobial susceptibility of neonatal IPD.  This study provides a background upon 111 
which to interpret changes that may occur in the post-vaccine era in neonates.    This 112 
study also provides useful baseline data for other LMICs who are still rolling out the 113 
PCV in their countries.114 
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Table 1:  Summary of neonatal invasive pneumococcal disease in different countries, 1975 – 2013 
Author Setting Design Study 
population 
EOD LOD PCV7a PCV13b Predominant 
serotypes 
Penicillin 
susceptibility 
Case 
fatality 
ratio 
(CFR) 
   N % (n) % (n) % (n) % (n)  % (n) % (n) 
Gomez M et al [8] Ohio, USA 1966-1998; Case reports and  
literature review; IPD, Age <30 days 
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86(87) 14(14)   3, 19  48(46) 
Hoffman JA et al 
[9] 
USA  1993 – 2001; Pediatric Multicentre  
Pneumococcal Surveillance Group;  
IPD, age ≤30 days 
21 14(3) 86(18) 75(15)  1, 3, 5, 12, 19 80(16) 14(3) 
Malhotra A et al 
[12] 
Melbourne, 
Australia 
2 years, 3 hospital sites 4 100(4) 0 25(1) 50(2)  50(2) 0 
Geelen SBM et al 
[14] 
The Netherlands 1975 – 1988; Neonatal ICU 7 100(7) 0   3, 19  43(3) 
Soto-Noguerón A 
et.al [15] 
Mexico  2000 -2014;  
National, PCV7 introduced in 2006;  
IPD and NIPDc, age < 60 days 
IPD = 69 26 (18) 74 (51) 34(43) 64(80)   13(7) 
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Table 1:  Summary of neonatal invasive pneumococcal disease in different countries, 1975 – 2013 
Author Setting Design Study 
population 
EOD LOD PCV7a PCV13b Predominant 
serotypes 
Penicillin 
susceptibility 
Case 
fatality 
ratio 
(CFR) 
   N % (n) % (n) % (n) % (n)  % (n) % (n) 
Kaltoft M et al 
[20] 
Denmark 1981-1999; National surveillance;  
IPD, age < 1 month 
44   30(12) 90(36) 1, 3, 19F, 4, 5, 
7F 
  
Ladhani SN et al 
[22] 
England and 
Wales 
1998 -2010; Health Protection  
Agency (HPA) IPD surveillance,  
PCV7 introduced in 2006; 
 IPD, age < 90 days 
480 
age <30 
days: 
N = 131 
74(97) 26(35) 22(27)   98(91) 9(12) 
Hans-Christian 
Slotved et al [35] 
Denmark  1943 – 2013; National, PCV7  
introduced 2007; IPD, age < 90 days 
216 33(72) d 67(144) e   1, 7F, 19F, 3, 
18C and 8 
  
Poehling KA et al 
[36] 
USA 1997-2004; Eight states in the USA;  
PCV7 introduced in 2000; IPD, age 0 – 
90 days  
146 
Age < 30 
days: 
N = 44 
68(30) 32(14) 38(56) 57(83) 6B, 19F, 23F 75%  
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Table 1:  Summary of neonatal invasive pneumococcal disease in different countries, 1975 – 2013 
Author Setting Design Study 
population 
EOD LOD PCV7a PCV13b Predominant 
serotypes 
Penicillin 
susceptibility 
Case 
fatality 
ratio 
(CFR) 
   N % (n) % (n) % (n) % (n)  % (n) % (n) 
Lagos R et al [37] Santiago, Chile 1994 – 2007; Metropolitan region;  
IPD, age 0 - 5 months 
430     1, 5, 14, 19F, 
19A 
 13(57) 
Bas AY et al [38] Turkey 1999 – 2008:  Tertiary hospital ICU –  
pneumococcal meningitis, age < 30 days 
8 13(1) 87(7)    100(8) 50(4) 
Olarte et al [39] Utah 1997-2010; Single tertiary  
children’s hospital; PCV7 introduced 
 2001; IPD, age 1 - 90 days 
36 
Age <30 
days: 
N = 6 
33(2) 67(4) 19(7) 69(25) 7F  50(3) 
Mount V et al [40] New Zealand 2009 – 2013; National surveillance; 
 IPD; PCV7 introduced in 2008; 
 age <90 days 
29 
Age < 30 
days: 
N = 19 
47(9) 53(10) 26(5) 74(14) 19F, 19A, 3 89(17) 11(1) f 
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Footnotes: 
Abbreviations – IPD = invasive pneumococcal disease; PCV = pneumococcal conjugate vaccine; EOD = early-onset disease (<7days old); LOD = late-
onset disease (≥7 – 28 days old); CFR = case fatality ratio; ICU = intensive care unit 
a   - seven -valent PCV; b – thirteen -valent PCV; c – NIPD = non-invasive pneumococcal disease; d – EOD was aged 0 -10 days; e - LOD was >10 -<89 
days; f - only EOD outcome was reported in this study
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CHAPTER 2:  MANUSCRIPT  115 
Title:  Invasive pneumococcal disease in neonates prior to pneumococcal conjugate 116 
vaccine use in South Africa: 2003 – 2008 117 
This manuscript has been prepared according to the instructions for authors for 118 
submission to Pediatric Infectious Diseases Journal (PIDJ).  The manuscript has been 119 
reviewed by PIDJ reviewers and corrections have been made.  A revised manuscript has 120 
been submitted to PIDJ and I am currently awaiting feedback from the editors. 121 
  122 
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Abstract 175 
Background: Neonatal invasive pneumococcal disease (IPD) in developing countries is 176 
poorly described.  We provide a baseline description of neonatal IPD in South Africa, 177 
prior to implementation of the seven-valent pneumococcal conjugate vaccine (PCV7) in 178 
2009. 179 
Methods: Data from children (age ≤ 2 years) with IPD (pneumococcus identified from a 180 
normally sterile specimen) from January 2003 - December 2008 were extracted from a 181 
national laboratory-based surveillance database.  Clinical and laboratory characteristics 182 
of IPD amongst neonates (0-27 days old) was compared to IPD amongst young children 183 
(≥28 days ≤ 2 years).  Early-onset IPD (EOD) (0 - 6 days old) was compared with late-184 
onset IPD (LOD) (≥7 – 27 days old).  Isolates were serotyped using the Quellung 185 
reaction. 186 
Results: Overall 27 630 IPD cases were reported.  Of the 26 277 (95%) with known 187 
ages, 6583 (25%) were ≤ 2 years of age, of which 4.5% (294/6583) were neonates.  The 188 
estimated annual incidence of neonatal IPD in 2008 was 5 per 100 000 live births.  189 
Fifty-one percent of neonates with IPD presented with EOD.  Case-fatality ratios (CFR) 190 
were high in both groups, 31% (28/89) in neonatal IPD vs 26%(614/2383) in non-191 
neonatal IPD (p=0.18).  Among neonates the meningitis cases (15/37, 41%) were 192 
associated with the highest CFR.  The thirteen-valent pneumococcal conjugate vaccine 193 
(PCV13) serotypes accounted for 69% (134/194) of neonatal IPD isolates. 194 
Conclusions: Pneumococcal neonatal disease in South Africa was not uncommon prior 195 
to PCV introduction, and is associated with a high CFR.  The indirect effect on neonatal 196 
IPD of PCV rollout requires further evaluation.  197 
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Introduction 198 
Invasive pneumococcal disease (IPD) is a significant cause of mortality and morbidity 199 
in children under five years of age, with the highest incidence (an estimated 75% of 200 
reported cases) in children ≤ two years of age [1, 2].  An estimated 6 – 8% of globally 201 
reported IPD in children under five years of age occurred in under two month old 202 
infants [3]. 203 
The estimated global incidence of neonatal IPD in 2010 was 36 per 100 000 live births, 204 
when many low-income countries were still not using the pneumococcal conjugate 205 
vaccine (PCV) [4].  This incidence however, varies markedly from low- and middle-206 
income countries (LMIC) such as Chile, with an incidence of 59 per 100 000 population 207 
[5], and high-income countries such as the USA and England and Wales, with an 208 
incidence of 11 – 13 per 100 000 live births [6, 7].  The incidence of neonatal IPD in 209 
South Africa, a middle-income country with a high maternal HIV infection rate, is not 210 
known [8]. 211 
Neonates are at risk for IPD via exposure to Streptococcus pneumoniae either during 212 
passage through the birth canal, by hematogenous spread in utero, or by horizontal 213 
spread from caregivers and siblings [9, 10].  Neonatal IPD has been categorized as 214 
early-onset disease (EOD) or late-onset disease (LOD) based on presentation in the first 215 
seven days of life or later [11].  The presenting clinical features are non-specific [12].  216 
Neonatal IPD isolates are reported to be more susceptible to antimicrobials than those 217 
found in older children [13].  The case fatality ratio (CFR) in neonatal IPD may be high, 218 
up to 50% [12]. 219 
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The seven-valent PCV (PCV 7) was introduced into the routine immunization schedule 220 
in South Africa in 2009, and replaced by the thirteen-valent PCV (PCV13) in 2011.  221 
Globally, most of the serotypes in neonatal IPD, serotypes 1, 3, 5, 12, 7F, are included 222 
in the PCV13 [13, 14].  Herd protection with use of PCV occurs through vaccinated 223 
individuals who are less likely to carry vaccine-type pneumococci, thus reducing 224 
transmission and conferring protection to those who are unimmunized [15].  Neonates 225 
may be protected by maternal antibodies or by the indirect effects of PCV.  There is 226 
currently no recommendation for routine immunization of pregnant mothers against 227 
pneumococcus [16,17].  The serotype distribution of neonatal IPD in South Africa and 228 
other developing countries prior to the introduction of PCV is largely unknown [4]. 229 
This study describes neonatal IPD, in the pre-PCV era, in South Africa, with the aim of 230 
providing baseline data to assist the interpretation of changes, with respect to incidence, 231 
serotype distribution, clinical presentation, and antimicrobial susceptibility, that may 232 
have occurred since the introduction of PCV.  In view of the lack of pre-vaccine data on 233 
neonatal IPD in LMICs, the findings in this study are also of value to other countries 234 
who are still in the introductory phases of PCV implementation [4].  235 
Neonatal IPD in South Africa: 2003 – 2008 
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Methods 236 
Ethics  237 
Ethical clearance was obtained from the Biomedical Research Ethics Committee of the 238 
University of KwaZulu-Natal (BE 012/010).  In addition, ethical clearance and 239 
permission to conduct laboratory-based and enhanced surveillance in South Africa for 240 
this study was obtained from the Health Research Ethics Committee (Human), 241 
University of Witwatersrand (Clearance number M02-10-42); the University of 242 
Stellenbosch Health Research Ethics Committee (Reference number N04/01/0021), the 243 
National Institute for Communicable Diseases Research Committee (Clearance number 244 
M060449); and the South African Department of Health (Reference H2/12/8). 245 
Surveillance  246 
Surveillance data were extracted from an ongoing, active, laboratory-based surveillance 247 
system, performed through GERMS-SA (Group for Enteric, Respiratory and Meningeal 248 
disease Surveillance in South Africa), commencing in 1999 and enhanced in 2003 [18].  249 
GERMS-SA is a national laboratory-based surveillance system that collects data and 250 
isolates from both the public and private sector laboratories in South Africa.  Their 251 
enhanced surveillance sites employ surveillance officers who perform follow-up on 252 
reported cases and populate case report forms (CRFs)with additional data such as 253 
admission dates, clinical diagnosis, outcome and HIV status.  The enhanced 254 
surveillance (ES) stabilized in 2005, and continued through 2008.  Reports and 255 
pneumococcal isolates from individuals with laboratory-confirmed IPD were submitted 256 
from > 130 laboratories (public and private sector) nation-wide to the National Institute 257 
for Communicable Diseases (NICD) in Johannesburg, South Africa.  Each report 258 
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contained patient demographic data including age, sex, date of specimen collection and 259 
specimen type.  Additional information including admission date, HIV status, clinical 260 
diagnosis, and outcome were collected only at the ES sites, 25 hospital-based 261 
laboratories in the nine provinces.  Surveillance officers documented outcome as in-262 
hospital mortality, or recovery.  Transferred cases were followed up.  Outcomes were 263 
unknown where children were removed from the hospital by caregivers prior to 264 
discharge or where it was inadvertently not documented.  Audits were performed using 265 
a laboratory information system (LIS) for the public sector laboratories (80 % of 266 
healthcare in South Africa), where all cases satisfying the case definition not already 267 
reported to the surveillance system were added to the database.  268 
Definitions 269 
IPD cases were defined as all children with a known age of ≤ 2 years with S. 270 
pneumoniae isolated from a normally sterile body site specimen, such as cerebrospinal 271 
fluid (CSF), blood, pleural and joint fluids, from January 2003 through December 2008, 272 
in South Africa.  Individuals who presented within 21 days with a second episode of 273 
IPD were excluded. 274 
Neonates were defined as infants 0 – 27 days of age.  We compared the characteristics 275 
of IPD in neonates with non-neonates (28 days to ≤ 2 years of age), the age group 276 
associated with the highest incidence of IPD. 277 
Early-onset disease (EOD) was defined where the specimen collection date was at age 278 
<7 days old, while late onset-disease (LOD) included all neonates with a specimen 279 
collection date at ≥ 7 - 27 days of age [19]. 280 
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Specimen source was defined according to the specimen type positive for 281 
pneumococcus as follows: CSF specimen, irrespective of any other specimen; blood 282 
specimen irrespective of other specimen type (excluding CSF); and “other” including all 283 
other normally sterile specimen types (excluding blood and CSF specimens). 284 
Clinical syndromes, available from ES sites only, were defined as: meningitis, as 285 
documented in clinical notes or if the IPD specimen was CSF; lower respiratory tract 286 
infection, as documented in clinical notes, together with culture of an isolate from a 287 
sterile site (including blood, pleural fluid); bacteremia without focus, where a focus was 288 
not documented and the specimen was blood; “other” included all cases not included in 289 
the definitions above. 290 
“Pediatric” serotypes were defined as serotypes 6B, 9V, 14, 19F, and 23F.  These have 291 
been defined as a group of serotypes associated with increased antimicrobial resistance 292 
and frequently isolated from children [20].  293 
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Incidence rates 294 
Incidence rates were calculated using the number of reported cases of IPD with known 295 
ages for each group as the numerator.  The denominator for neonates was live births for 296 
each year, while that for the non-neonates was the number of one-month-old children 297 
subtracted from the mid-year population estimates for ≤ 2-year-old children, for each 298 
year.  The population estimates were extracted from Statistics South Africa [21].  299 
Incidence was reported per 100 000 population. 300 
Microbiology and serotyping 301 
Identification of the submitted pneumococcal isolates was confirmed at the NICD using 302 
standard microbiological techniques i.e. colony morphology, haemolysis and optochin 303 
susceptibility.  Serotyping was performed with the Quellung reaction, using specific 304 
pneumococcal antisera (Statens Serum Institut, Copenhagen, Denmark).  The serotypes 305 
included in PCV7 are 4, 6B, 9V, 14, 18C, 19F and 23F.  PCV10 includes three 306 
additional serotypes: 1, 5, 7F, and PCV 13 an additional 3: 3, 6A, 19A [2]. 307 
All isolates were screened for penicillin resistance by disk diffusion testing using a 1µg 308 
oxacillin disk (Mast diagnostics, Merseyside, United Kingdom).  Isolates testing non- 309 
susceptible on screening had minimum inhibitory concentrations (MICs) determined by 310 
agar dilution or Etest® (AB-Biodisk, Solna, Sweden) for penicillin and ceftriaxone.  311 
Isolates were also tested against the following agents using the disk diffusion method: 312 
erythromycin, clindamycin, chloramphenicol, tetracycline, rifampicin, cotrimoxazole 313 
and ofloxacin - if non-susceptible, MICs were determined by Etest®.  Results were 314 
interpreted using Clinical and Laboratory Standards Institute (CLSI) 2013 guidelines 315 
[22].  Isolates were considered non-susceptible to penicillin at MICs ≥ 0.12 mg/L using 316 
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the parenteral penicillin meningitis breakpoints.  For other antimicrobial agents, isolates 317 
were defined as non-susceptible if they were intermediately or fully resistant to the 318 
agent tested.  Multidrug-resistance (MDR) was defined as non-susceptibility to at least 319 
one agent in three or more different classes [23]. 320 
The recommendation for HIV testing at the time of the study was to perform a 321 
qualitative DNA polymerase chain reaction for children < 18 months of age and an 322 
enzyme linked immunosorbent assay (ELISA) for children ≥ 18 months of age [24], as 323 
requested by the attending clinician. 324 
Statistical analysis 325 
Medians and interquartile ranges are presented for continuous variables and frequencies 326 
are presented for categorical variables.  Chi-square tests are used to compare groups.  A 327 
p value (2-tailed) of ≤ 0.05 was considered significant.  Epi Info™ version 7.2.1.0 was 328 
used to analyse the data.  329 
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Results 330 
Demographics 331 
There were 27 630 reported IPD cases from January 2003 through December 2008, 26 332 
277 (95%) with known ages, of whom 25% (6 583) were aged ≤ 2 years, and 4.5% 333 
(294/6583) of these were neonates.  Forty-two percent (2747/6583) of IPD cases were 334 
from ES sites, which included 31% (92/294) neonates and 42% (2655/6289) non-335 
neonates (p < 0.01) (Table 1).  In 2008, the national incidence of neonatal IPD was 5 336 
per 100 000 live births, 22-fold lower than the non-neonatal incidence of 110 per 100 337 
000 population (Figure 1).  The change in incidence was relatively stable from 2003 – 338 
2008 among both neonates and non-neonates (p = 0.05) except for a peak in neonatal 339 
incidence in 2007 (from 44 cases in 2006 to 70 cases in 2007) (Figure 1).  There was no 340 
spatial or serotype clustering among these cases.   341 
Although there was some variation in IPD incidence in the nine provinces, there was no 342 
statistically significant difference in provincial incidence when neonates were compared 343 
to non-neonates (data not shown).   344 
The median age among neonates was six days (IQR 1.5 – 14) and among non-neonates 345 
was 231 days (IQR 127 – 386).  There were more females among the neonates 346 
(151/286, 53%) than non-neonates (2788/6113, 46%) (p = 0.02) (Table 1, sex not 347 
documented in six neonates and 176 non-neonates).  Of the 43 (43/92, 47%) neonates 348 
tested for HIV 44% (19/43) were HIV infected while 67% (1218/1831) of tested non-349 
neonates (1831/2655, 69%) were HIV infected (p < 0.01) (Table 1).  This difference 350 
was mainly because of a smaller proportion of EOD cases being HIV positive (4/16, 351 
25%) than LOD cases (15/27, 56%; p = 0.1).  352 
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Clinical features and case-fatality ratios (CFR) 353 
Clinical syndromes were available from 91/92 neonates and 2647/2655 non-neonates 354 
from ES sites only.  Neonates presented most frequently with meningitis (36/91; 40%) 355 
compared to non-neonates (898/2647; 34%, p = 0.3) (Table 1).  Non-neonates presented 356 
most frequently with lower respiratory tract infections (1318/2647; 50%) compared to 357 
neonates (28/91; 31%, p < 0.01).   358 
The outcomes were available for 90/92 neonates and 2627/2655 non-neonates from the 359 
ES sites.  The neonatal CFR was 31% (28/90), while the non-neonatal CFR was 26% 360 
(676/2627) (p=0.13) (Table 1).  Cases with meningitis had the highest CFR among both 361 
neonates (39%; 14/36) and non-neonates (37%; 327/882) (Table 2).  362 
Serotype distribution  363 
Viable isolates were available for 76% (5021/6583) of reported cases, 195 neonatal and 364 
4826 non-neonatal isolates.  There were 16 isolates that were non-typeable, 1 neonatal 365 
and 15 non-neonatal. PCV7 serotypes were responsible for 31% (61/194) neonatal IPD 366 
and 59% (2853/4811) non-neonatal IPD (p < 0.05) (Table 1).  The PCV13 serotypes 367 
were responsible for 69% (134/194) of IPD in neonates and 84% in non-neonates (4 368 
042/4 811) (Table 1).  The proportion of PCV7 and PCV13 serotypes responsible for 369 
IPD in neonates was significantly lower than in non-neonates (p < 0.01) (Table 1).  370 
Forty-six percent (90/194) of neonatal IPD were accounted for by serotypes 5 (n = 18), 371 
1 (n = 17), 19F (n = 15), 3 (n = 14), 8 (n = 13) and 14 (n = 13).  These serotypes were 372 
responsible for 33% (1 572/4 811) of non-neonatal IPD serotypes (p<0.01) (Figure 2).  373 
Serotypes 1, 3 and 5 were more frequently isolated among neonates, 25% (49/194), than 374 
among non-neonates, 5% (247/4 811) (p<0.01) (Figure 2).  The most common non-375 
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neonatal serotypes were 14 (n = 805), 6B (n = 618), 6A (n = 580), 23F (n = 542), 19F (n 376 
= 520) (Figure 2).  The non-PCV13 serotypes 8, 12F and 13 accounted for 13% 377 
(25/194) of neonatal and 4% (183/4811) of non-neonatal isolates (Figure 2). 378 
Antimicrobial susceptibility  379 
Antimicrobial susceptibility testing was performed on all 5021 viable isolates.  Among 380 
neonates 76% (148/195) of isolates were susceptible to penicillin, compared to 50% 381 
(2424/4826) non-neonatal IPD isolates (p<0.01) (Table 1).  Most isolates in this study 382 
were susceptible to ceftriaxone, 99% (194/195) and 98% (4757/4826) among neonates 383 
and non-neonates, respectively (Table 1).  Cotrimoxazole non-susceptibility was lower 384 
among neonates (77/195, 39%) than non-neonates (3542/4826, 73%) (p <0.01) (Table 385 
1). Among all tested isolates, 27%(1 361/5 021) were MDR, of which 15% (30/195) 386 
were neonatal and 28% (1 331/4 826) non-neonatal isolates (p <0.01) (Table 1). 387 
Six serotypes most commonly associated with non-susceptibility to penicillin were 388 
serotypes 14, 19F, 6B, 23F, 6A and 19A.  These accounted for 89% (42/47) and 91% 389 
(2124/2402) of penicillin non-susceptible isolates among neonates and non-neonates, 390 
respectively (Figure 3).  These six serotypes were also the most frequent among the 391 
MDR isolates.  Serotype 14 was the predominant MDR serotype: 40% (12/30) and 51% 392 
(684/1 331) in neonates and non-neonates, respectively (Figure 3). 393 
Early-onset vs. late-onset disease  394 
Fifty-one percent (149/294) of neonates presented with EOD (Table 3).  The median age 395 
for EOD was 0 days (IQR 0 – 2), with 66% (99/149) presenting within 48 hours of 396 
birth.  The median age for LOD was 14 days (IQR 10 - 22).  The EOD patients were 397 
more likely to have blood specimen sources than LOD patients (110/149, 74% vs. 398 
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76/145, 52%, p <0.01, Table 3).  LOD cases presented with meningitis more frequently 399 
than EOD cases (LOD: 25/48; 52% vs EOD: 11/43; 26%,  p = 0.01) (Table 3).   The 400 
CFR was high in EOD and LOD, (14/44, 32% and 14/48, 29%, respectively).  401 
Pneumonia in EOD (6/14, 43%) was associated with a higher CFR than in LOD, (1/14, 402 
7%) (p < 0.03), while meningitis contributed substantially to the high CFR in both 403 
groups, (4/11, 36% in EOD; 10/25, 40% in LOD) (p = 0.7) (Table 4).  404 
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Discussion 405 
In this study, conducted prior to introduction of PCV7 vaccination in South Africa, 406 
neonatal IPD accounted for an estimated 4,5% of IPD cases in children ≤ 2 years of age.  407 
Almost 50% of these neonates presented within the first week of life, with meningitis 408 
and bacteremia without focus, being the predominant clinical presentations.  PCV13 409 
serotypes contributed to 69% of all neonatal cases.  The most frequent neonatal 410 
serotypes 1, 3 and 5 accounted for 25% of neonatal and only 5% of non-neonatal IPD 411 
cases.  Neonatal IPD was associated with a high CFR (31%). 412 
The national incidence of neonatal IPD, 5 per 100 000 live births in South Africa in 413 
2008, was lower than the estimated global incidence of 36 per 100 000 live births in 414 
2010 [4].  Billings et al reported an incidence of 16 per 100 000 live births, prior to the 415 
introduction of PCV, in less-developed United Nations (UN) strata countries [4].  Our 416 
incidence is also much lower than the incidence reported in Chile, of 59 per 100 000 417 
population, and closer to that reported in the USA in 2006 (11 per 100 000 live births), 418 
and in England and Wales in 2013 (13 per 100 000 live births) prior to PCV, among 419 
<90 day old infants [5, 6, 7].  The incidence in this study is similar to that reported by 420 
Cutland et al, from a South African city, Soweto, where the incidence of neonatal sepsis 421 
due to the pneumococcus was reported as 8 per 100 000 live births among neonates 422 
[25].  In the Sowetan study S. pneumoniae was noted to occur less frequently than other 423 
common causes of neonatal sepsis, such as Streptococcus agalactiae, Staphylococcus 424 
aureus, Streptococcus viridans and Escherichia coli [25].  Differences in incidence may 425 
be attributed to the higher threshold for taking blood culture specimens in neonatal units 426 
in South Africa, variation in surveillance methodologies and completeness in reporting 427 
[4, 7].  The incidence we report may be an underestimate of true neonatal incidence as 428 
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infants with clinically evident, but microbiologically negative, sepsis would not have 429 
been included in this study.  In addition, the sensitivity of cultures among neonates is 430 
low, attributable to inadequate sample volumes being submitted, as well as empiric 431 
antimicrobials being commenced prior to cultures being taken [26, 27]. 432 
Among South African neonates, a large proportion of IPD cases, 51%, presented with 433 
EOD, similar to high-income countries like the USA and UK where 70% (19/27) and 434 
77% (101/131), respectively, of neonatal IPD cases had EOD [5, 6].  This contrasts with 435 
studies from Utah and Mexico, where only 11% (2/9) and 20% (25/126) of neonatal 436 
cases, respectively, were EOD [28, 29].  The higher rates of EOD in South African 437 
neonates and those of the USA and England and Wales may be due to similar at risk 438 
populations, access to care and specimen-taking practices [4].  The variation between 439 
and within countries may be attributed to differences in small hospital-based studies, 440 
socioeconomic status, access to antenatal care and maternal and infant risk factors [28, 441 
29]. 442 
In this study, 66% (99/149) of the EOD neonates presented within the first 48 hours of 443 
life, similar to that reported by Ladhani et al in the UK, 67% (84/101), who indicated 444 
that these infants were more likely to be premature [7].  Early-onset sepsis has been 445 
found to be associated with prematurity, maternal chorioamnionitis, or social factors 446 
influencing prenatal care [30].  We were unable to analyse for prematurity or other 447 
maternal factors as these data were not collected during the study period.   448 
Although the association of IPD and HIV infection in children has been well 449 
documented in South African children [31], this was not clear among neonates in this 450 
study.  The high rates among neonates with IPD, 44%, may be because children that 451 
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were most ill or had signs of HIV were preferentially tested, or would have presented to 452 
a healthcare setting.  In addition, HIV status data was only available for 15% (43/294) 453 
of neonates as there was no policy for universal HIV testing at birth at the time of this 454 
study.  While the lower HIV positivity rate among the EOD cases was responsible for 455 
the significantly lower HIV positivity rate among neonates, compared to non-neonates, 456 
this observation cannot be explored further as the numbers tested were very low. 457 
We observed a female sex preponderance in this study.  Two studies, in Mexico and 458 
Denmark, reported a male sex preponderance [29, 32], while others do not report a sex 459 
preponderance [4, 5] among neonates with IPD.  A male sex predisposition to neonatal 460 
sepsis, particularly Gram-negative sepsis, has been attributed to x-linked 461 
immunoregulatory genes [33, 34].  This predisposition may be specific to Gram-462 
negative sepsis in neonates and therefore not consistently observed in neonatal IPD. 463 
The predominant clinical presentation of neonates, bacteremia (42%) among EOD 464 
cases, and meningitis (52%) among LOD cases, in the South African setting was 465 
consistent with findings from England and Wales, and Mexico [7, 29].  Ladhani et al 466 
and Soto-Noguerón A et al reported bacteremia as the predominant presentation in the 467 
EOD cases and meningitis in the LOD cases [7, 29].  The more frequent diagnosis of 468 
bacteremia, and blood specimens in this study, among EOD cases may relate to an 469 
inability of the immature immune system in these very young babies to localize the 470 
infection [30, 35].   471 
Although the CFR among neonates (31%) was higher than that among non-neonates 472 
(26%), this did not reach statistical significance.  The neonatal CFR was also lower than 473 
those in other studies in England and Wales and the USA [7, 12].  This may be 474 
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attributed to an underestimation of the neonatal CFR, as infants who demised at home 475 
would not have been included in this database.  In addition, only 32% (90/294) of 476 
neonates with IPD had outcomes available for analysis.  Meningitis, an established risk 477 
factor for death in patients with IPD [7, 36], was associated with the highest CFR 478 
among both neonates and non-neonates in this South African context.  The CFR in 479 
neonates with IPD in this study was higher than that of neonates with sepsis due to more 480 
frequently encountered pathogens, such as Group B Streptococcus, 16,9% [25] or 481 
Escherichia coli, 6% [37], in South Africa. 482 
In this study the neonatal isolates were generally more susceptible to antimicrobials 483 
tested (penicillin and ceftriaxone) than the non-neonatal isolates, as in the USA and 484 
Mexico, prior to PCV7 [12, 29].  This is not unexpected as the neonatal serotypes, 485 
unlike the pediatric serotypes, are usually not associated with antimicrobial resistance 486 
[14, 38, 39]. 487 
Our findings of 31% PCV7 serotypes in neonatal IPD are consistent with pneumococcal 488 
vaccine studies from Mexico (34%), and England and Wales (44%), prior to PCV7 [29, 489 
7].  The PCV13 serotype coverage among neonatal IPD isolates (69%) was also 490 
comparable to those in Mexico (64%), and England and Wales (67%) [29, 7].  While 491 
69% of neonatal IPD were due to PCV13 serotypes, this was significantly less than that 492 
observed in the non-neonatal IPD group (84%). The common neonatal IPD serotypes 1, 493 
3 and 5 among South African neonates is consistent with other studies from the USA 494 
and Denmark [12, 32].  These serotypes have been reported to occur more frequently 495 
among adults than children in the UK, Denmark, and South Africa [7, 32, 31].  This 496 
supports the widely accepted premise of neonatal IPD being acquired via horizontal 497 
spread from mother or adult caregiver [9].   498 
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Herd protection has been reported to play a role in decreasing the incidence of IPD in 499 
infants too young to be immunized, in studies post-PCV7 in England and Wales, USA 500 
and in South Africa [6, 7, 40].  However, no change was observed in PCV7 IPD in 501 
Mexico, in infants < 60 days old, after the introduction of PCV7, suggesting that herd 502 
protection did not extend to the mothers of these infants [29].  The option of maternal 503 
vaccination in such a setting, although reported to be safe, is currently not 504 
recommended due to insufficient evidence that it will provide neonatal protection [16, 505 
17]. 506 
This study has several limitations.  First, the data were collected using a laboratory-507 
based surveillance system, where isolate submission is dependent on diligent local 508 
laboratory and surveillance staff.  Case ascertainment also suffers from differential 509 
access to care and specimen-taking practices throughout the country.  Only cases with 510 
known ages were included. In addition, audits performed on the surveillance database 511 
did not include private sector cases.  Therefore, our estimates are an underestimation of 512 
actual disease burden in children ≤ 2 years old in South Africa.  Second, as the study 513 
was performed retrospectively we were unable to check for maternal factors, such as 514 
premature labor, preterm rupture of membranes, maternal HIV infection, vaginal 515 
colonization or maternal IPD.  Neonatal data, especially relating to HIV infection and 516 
outcomes, were also incomplete in our database.  Third, susceptibility tests results were 517 
interpreted using meningitis breakpoints irrespective of the clinical syndrome, therefore 518 
the resistance rates appear higher in this study. This was appropriate as our study looked 519 
at trends over time, and not treatment outcomes.  Fourth, susceptibility testing for 520 
ceftriaxone was revised from an agar dilution method to a CLSI-recommended broth 521 
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microdilution method, using TREK panels, in 2009 [22], as the agar dilution method 522 
was found to underestimate beta-lactam resistance [41].   523 
Since 2014, there has been renewed global interest in neonatal mortality, the primary 524 
cause of which is neonatal sepsis [42].  The highest mortality rates have been reported 525 
in sub-Saharan Africa [42].  In this setting, this study is well-timed in describing IPD in 526 
this vulnerable group.   527 
Our findings suggest that the pneumococcus, while not as common a cause of neonatal 528 
sepsis as other agents like Group B Streptococcus or E.coli, is associated with a higher 529 
CFR. Neonatal IPD in this country is found to be similar to neonatal IPD in other 530 
countries in terms of clinical presentation, serotype distribution, antimicrobial 531 
susceptibility, and CFRs.  The findings in this study establish a baseline against which 532 
to interpret changes that may occur in neonatal IPD since the implementation of PCV in 533 
South Africa.    534 
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Table 1: Characteristics of invasive pneumococcal disease in children ≤ 2 years of age in South Africa, 2003 – 2008, by age group 
(neonates vs non-neonates) 
Characteristic Age group   
  < 28 days ≥28 days ≤2 years  Total 
  N=294 N=6289 p value N=6583 
  n (%) n (%)  n (%) 
Sexa Female 151 (53) 2788 (46) 0.02 2939 (46) 
Specimen Cerebrospinal fluid 106 (36) 2178 (35) 0.67 2284 (35) 
 Blood 186 (63) 3957 (63) 0.95 4143 (63) 
 Other 2 (1) 154 (2)  156 (2) 
Enhanced surveillance sites 
(ES)b 
Yes  92 (31) 2655 (42) <0.01 2747 (42) 
HIV statusc Positive 19 (44) 1218 (67) <0.01 1237 (66) 
 Negative 24 (56) 613 (33)  637 (34) 
 Tested 43 (47) 1831 (69) < 0.01 1874 (68) 
Clinical presentationd Meningitis 36 (40) 898 (34) 0.3 934 (34) 
 Pneumonia 28 (31) 1318 (50) <0.01 1346 (49) 
 Bacteremia 27 (30) 185 (7) <0.01 212 (8) 
 Other ͤ 0 246 (9)  246 (9) 
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Characteristic Age group   
  < 28 days ≥28 days ≤2 years  Total 
  N=294 N=6289 p value N=6583 
  n (%) n (%)  n (%) 
Antimicrobial susceptibilityᶠ Penicillin NS 47 (24) 2405 (50) <0.01 2449 (49) 
 Ceftriaxone NS 1 (1) 69 (1)  70 (1) 
 Cotrimoxazole NS 77 (39) 3542 (73) <0.01 3619 (72) 
Multidrug-resistance Yes 30 (15) 1331 (28) <0.01 1361 (27) 
PCV serotypes PCV7 61 (31) 2835 (59) <0.01 2896 (58) 
 PCV13 134 (69) 4042 (84) <0.01 4176 (84) 
Outcomesᶢ Demised 28 (31) 676 (26) 0.13 704 (26) 
Footnotes: Abbreviations – HIV = Human immunodeficiency virus, NS = non-susceptible 
ͣ There were 8 neonates and 176 non-neonates with sex unknown. b There were 92 neonates and 2655 non-neonates from ES sites.  ͨHIV test results (ES 
sites only), were not available for 49/92 neonates and 824/2655 non-neonates.   ͩ The denominator for diagnosis included all children from ES sites, and 
excluded those where no diagnosis was recorded: 9 neonates and 8 non-neonates, therefore 91 neonates and 2647 non-neonates were included in this 
analysis.  The clinical diagnosis recorded in the category “other” included gastroenteritis (n = 194), soft tissue, bone, and joint infections (n = 42), other 
diagnoses (n = 10).  ᶠ There were 5021 viable isolates with susceptibility data available, N = 195 neonates and N = 4826 non-neonates.  ᶢ Outcomes 
were available for 90/92 neonates and 2627/2655 non-neonates (ES sites only).    
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Table 2:  Case-fatality ratios (CFR) in children ≤ 2 years of age with invasive pneumococcal disease in South Africa, by age group 
(neonates vs. non-neonates) and clinical presentation, 2003 - 2008 
Clinical syndrome Age group  
 < 28 days ≥28 days ≤2 years p-value Total 
 CFR (n/N) CFR (n/N)  CFR(n/N) 
Meningitis 39 (14/36) 37 (327/882) 0.8 37 (341/918) 
Pneumonia 25 (7/28) 19 (245/1310) 0.4 19 (252/1338) 
Bacteremia 17 (6/25) 21 (39/182) 0.7 22 (45/207) 
Footnote:  Abbreviations – CFR = case fatality ratio.   
The clinical category of “other” (n = 246) was excluded from the analysis of case-fatality ratios by clinical syndrome, as there were no neonatal cases in 
this category.  The cases without a clinical diagnosis, 1 neonate and 8 non-neonates, were excluded, as were the 2 neonates and 28 non-neonates whose 
outcomes were not available.  Final denominators used:  Neonates = 89; Non-neonates = 2374.   
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Table 3: Characteristics of neonates with invasive pneumococcal disease in South Africa: 2003 – 2008, by age of presentation: early 
versus late-onset disease 
  Early-onset disease (0 – 6 days old) Late-onset disease (≥7 < 28 days old)  
  N = 149 N = 145 p value 
  n (%) n (%)  
Sexa Female 73 (51) 78 (55) 0.55 
Specimen Cerebrospinal fluid 39 (26) 67 (46) <0.01 
 Blood 110 (74) 76 (52) <0.01 
 Other 0 2 (1)  
ES sites Yes 44 (48) 48(52) 0.60 
HIV statusᵇ Positive 4 (25) 15 (56) 0.1 
 Negative 12 (75) 12 (44)  
 Tested 16 (36) 27 (56) 0.1 
Clinical presentationc Meningitis 11 (26) 25 (52) 0.01 
 Pneumonia 14 (33) 14 (29) 0.9 
 Bacteremia 18 (42) 9 (19) 0.02 
Outcomesd Demised 14/42 (33) 14/48 (29) 0.70 
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  Early-onset disease (0 – 6 days old) Late-onset disease (≥7 < 28 days old)  
  N = 149 N = 145 p value 
  n (%) n (%)  
     
Antimicrobial 
susceptibility 
Penicillin NS 24 (24) 23 (24) 0.96 
Multidrug resistant Yes 13 (13) 17 (18) 0.38 
PCV serotypese PCV7 31 (31) 30 (32) 1.00 
 PCV13 63 (64) 71 (75) 0.09 
Footnotes:  Abbreviations – ES = enhanced surveillance sites, NS = non-susceptible, EOD = early-onset disease, LOD = late-onset disease, PCV = 
pneumococcal conjugate vaccine. 
ͣ Sex – there were 6 EOD and 2 LOD cases where the sex was unknown.  ᵇ HIV status was not known in 28 EOD and 21 LOD cases from ES sites.  ͨ 
There were 91 neonates, 43 with EOD and 48 with LOD, with known clinical diagnoses.  ͩ Two cases from the ES sites did not have a documented 
outcome.  e There was 1/195 viable isolates that was non-typeable among the LOD cases. 
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Table 4:  Case-fatality ratios (CFR) in children < 28 days of age with invasive pneumococcal disease in South Africa, by age of 
presentation (early vs. late-onset disease) and clinical presentation, 2003 – 2008 
 Early-onset disease Late-onset disease  
 < 7 days ≥7days – < 28 days p value 
 CFR (n/N) CFR (n/N)  
Meningitis 36 (4/11) 40 (10/25) 0.7 
Pneumonia 43 (6/14) 7 (1/14) 0.03 
Bacteremia 19 (3/16) 33 (3/9) 0.5 
Footnote:  Abbreviations – EOD = early-onset disease, LOD = late-onset disease, CFR = case fatality ratio 
Two of the 92 neonates from ES sites did not have an outcome documented.  These 2, as well as the one neonate with an unknown clinical diagnosis, 
were excluded from the further analysis of CFR by clinical syndrome. 
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Figure 1: Incidence rates* (showing 95% confidence intervals) of invasive pneumococcal disease in neonates and non-neonates “(≥ 
28 days - ≤ 2 years), by year, South Africa, 2003-2008 (n=6,583)  
* Incidence rates were calculated based on population denominators provided by Statistics South Africa, and are expressed as cases per 100,000 
population 
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Figure 2: Most common serotypes among children ≤ 2 years of age, with invasive pneumococcal disease in South Africa: 2003 – 
2008 by age group (neonates versus non-neonates) (* = PCV13 serotypes) 
0
5
10
15
20
25
30
35
5* 1* 19F* 3* 14* 8 6A* 6B* 19A* 18C* 23F* 12F 13 4* 7F* 9V* NT Other
P
er
ce
n
ta
g
e 
se
ro
ty
p
es
 i
so
la
te
d
Serotypes
Neonates (N = 195) Non-neonates (N = 4826)
Neonatal IPD in South Africa: 2003 – 2008 
 
48 
 
 
Figure 3:  Serotype distribution of penicillin non-susceptible and multi-drug resistant(MDR) invasive pneumococcal disease 
isolates in children ≤ 2 years of age in South Africa, 2003 -2008, by age group 
Footnote:  Abbreviations:  NS = non-susceptible; MDR = multi-drug resistant.  These 7 serotypes accounted for 91% (43/47) of the penicillin non-
susceptible neonatal isolates.   Serotype 19F was the only serotype where the % neonatal penicillin non-susceptible isolates exceeded that of the non-
neonates (p = 0.03).  ᵟSerotype 14 was associated with the most multi-drug resistance among both neonates and non-neonates.
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CHAPTER 4:  APPENDICES 
1. Approval letters from post-graduate office (UKZN) and ethics committee (UKZN) 
2. Valid ethics certificate 
3. Case report form – NICD  
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2. Ethics certificate 
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3. Case report form (CRF) 
These were the forms utilized by the surveillance officers,from NICD, to collect 
additional data from patients presenting at one of the enhanced surveillance 
sites.  The additional data included clinical diagnosis, outcomes, HIV status.  
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